monoclonal antibodies

October 6, 2022

Vanderbilt’s Crowe receives the Building the Foundation Award from Research!America

Vanderbilt’s James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization.

By Bill Snyder
Networked dots in the shape of a brain
October 3, 2022

Minority patients less likely to have amyloid plaques necessary for Alzheimer’s treatments

Fewer Black, Hispanic and Asian patients meet biomarker qualifications for landmark treatments that may slow the progression of Alzheimer’s disease by targeting amyloid plaques, according to new findings published in JAMA Neurology.

By Holly Fletcher
September 29, 2022

VUMC lands grant to build top-line biosafety facility

Vanderbilt University Medical Center is set to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms.

By Bill Snyder
Shown here is the research team that discovered monoclonal antibodies that protect against COVID-19 in high-risk individuals.
August 24, 2022

COVID antibody research conducted at VUMC lands national award

A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.

By Bill Snyder
June 8, 2022

Research probes cause of acute flaccid myelitis in children

Research that began at Vanderbilt University Medical Center has found evidence that a viral infection followed by a “robust” immune response is the cause of a polio-like paralyzing illness in children called acute flaccid myelitis (AFM).

By Bill Snyder
March 31, 2022

Crowe receives national award for COVID antibody research

Vanderbilt’s James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19.

By Bill Snyder
March 10, 2022

Technique hastens COVID-19 antibody discovery

Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.
By Bill Snyder
February 17, 2022

Pandemic leads to broader use of monoclonal antibodies

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
By Bill Snyder
January 20, 2022

Omicron evades some but not all monoclonal antibodies: study

A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.
By Bill Snyder
December 24, 2021

Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate

New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death.
By Tom Wilemon
December 9, 2021

Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization

The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which  protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
By Bill Snyder
December 2, 2021

Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms

By Bill Snyder
November 18, 2021

Seven from VUMC among most highly cited researchers

Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
By Bill Snyder